Gianna is an associate editor of The American Journal of Managed Care® (AJMC®). She has been working on AJMC® since 2019 and has a BA in philosophy and journalism & professional writing from The College of New Jersey.
A new analysis from the REDUCE-IT trial finds that cardiovascular benefits of Vascepa are consistent no matter what type of statin a patient takes for cholesterol.
The benefits of taking icosapent ethyl, the purified omega-3 fatty acid sold as Vascepa, were consistent across statins of different strengths and types, according to the latest data from the REDUCE-IT study presented during the 2020 Congress of the European Society of Cardiology (ESC), being presented in a virtual format.
Icosapent ethyl, first approved to treat high triglycerides, has since received a cardiovascular (CV) indication after REDUCE-IT showed that a 4g per day dose reduced the risk of first-time CV events by 25% and first and future events by 30%. Subsequent studies have sought to better understand the mechanisms of how icosapent ethyl produces these results.
In this latest round of data from the study, lead study author Deepak Bhatt, MD, MPH, of Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, sought to examine the relationship between low density lipoprotein (LDL) cholesterol pathways and the CV benefits of icosapent ethyl, by examining whether the there were major differences in benefit by statin type or by statin group (lipophilic vs lipophobic); according to the abstract presented at ESC, 96.1% of the patients in the study fell into one of these statin groups.
In an interview, Bhatt told The American Journal of Managed Care® that the analysis further supports the main findings of REDUCE-IT. “We looked at patients who are on really intense statins, things like atorvastatin and rosuvastatin, or more modest types of statins, such as simvastatin or pravastatin,” he said. “We also bunched it by hydrophobic and hydrophilic statins.”
“The bottom line was, any way you sliced it there was a benefit, a consistent benefit favoring icosapent ethyl versus placebo, irrespective of the actual statin type or category of statin.”
Results. CV outcomes were similar across different statin types (interaction, P = .61) and across lipophilic/lipophobic categories (interaction, P = .51). Hazard ratio (HR) results by individual statin type were as follows, all favoring icosapent ethyl (all 95% CI):
Among the 2 main statin groups, the HR on lipophilic statins was 0.78 (0.69-0.87), P < .0001; for lipophobic statins, HR, 0.73 (0.66-0.88), P = .0012.
In the abstract, Bhatt and co-authors wrote that the LDL cholesterol changes and CV risk reduction in the study “appear independent of the type of concomitant statin therapy.”
They concluded, “These data provide clinicians with additional insight regarding concomitant statin therapy considerations when prescribing icosapent ethyl and suggest there are important mechanisms of action for the substantial CV risk reduction observed with icosapent ethyl that are distinct from the LDL receptor pathway.”
Bhatt DL, Miller M, Steg P, for the REDUCE-IT Investigators. REDUCE-IT outcomes by baseline statin type. Presented at ESC Congress 2020:. Abstract 218514.